$京东(JD)$ 11。11。11。_老虎社区_美港股上老虎 - 老虎社区

点赞
评论
收藏

幸运无敌_8833
2023-10-03

$京东(JD)$ 11。11。11。

美股异动 | 将被礼来收购，Point Biopharma盘前涨超82%

10月3日，Point Biopharma盘前直线涨超82%，礼来以12.50美元/股的价格将其收购

美股异动 | 将被礼来收购，Point Biopharma盘前涨超82%

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

点赞

举报

评论

推荐
最新

empty

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":226607236358392,"tweetId":"226607236358392","gmtCreate":1696332101119,"gmtModify":1696334095456,"author":{"id":3569549791948201,"idStr":"3569549791948201","authorId":3569549791948201,"authorIdStr":"3569549791948201","name":"幸运无敌_8833","avatar":"https://static.tigerbbs.com/9dacd5d2a7077a41b394190b7ed47d47","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/JD\">$京东(JD)$&nbsp;</a>11。11。11。</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/JD\">$京东(JD)$&nbsp;</a>11。11。11。</p></body></html>","text":"$京东(JD)$ 11。11。11。","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/226607236358392","repostId":1150270900,"repostType":2,"repost":{"id":"1150270900","kind":"news","weMediaInfo":{"introduction":"为用户提供金融资讯、行情、数据，旨在帮助投资者理解世界，做投资决策。","home_visible":1,"media_name":"老虎资讯综合","id":"102","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1696330222,"share":"https://www.laohu8.com/m/news/1150270900?lang=&edition=full","pubTime":"2023-10-03 18:50","market":"us","language":"zh","title":"美股异动 | 将被礼来收购，Point Biopharma盘前涨超82%","url":"https://stock-news.laohu8.com/highlight/detail?id=1150270900","media":"老虎资讯综合","summary":"10月3日，Point Biopharma盘前直线涨超82%，礼来以12.50美元/股的价格将其收购","content":"<html><head></head><body><p>10月3日，Point Biopharma盘前直线涨超82%，<a href=\"https://laohu8.com/S/LLY\">礼来</a>将以12.50美元/股的现金价格收购Point Biopharma。交易总金额约为14亿美元，该交易不受任何融资条件的约束，交易预计将于2023年底完成。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c2babea8249e8c38accee176b179d490\" title=\"\" tg-width=\"817\" tg-height=\"480\"/></p><p>资料显示，Point Biopharma成立于2019年，该公司专注于用于治疗癌症的下一代放射性药物的开发和商业化。该公司还拥有大型放射性配体制造园区和放射性配体研发平台。礼来希望通过收购Point Biopharma将其肿瘤学业务拓展到下一代放射性配体疗法。</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>美股异动 | 将被礼来收购，Point Biopharma盘前涨超82%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n美股异动 | 将被礼来收购，Point Biopharma盘前涨超82%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/102\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">老虎资讯综合 </p>\n<p class=\"h-time\">2023-10-03 18:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p>10月3日，Point Biopharma盘前直线涨超82%，<a href=\"https://laohu8.com/S/LLY\">礼来</a>将以12.50美元/股的现金价格收购Point Biopharma。交易总金额约为14亿美元，该交易不受任何融资条件的约束，交易预计将于2023年底完成。</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/c2babea8249e8c38accee176b179d490\" title=\"\" tg-width=\"817\" tg-height=\"480\"/></p><p>资料显示，Point Biopharma成立于2019年，该公司专注于用于治疗癌症的下一代放射性药物的开发和商业化。该公司还拥有大型放射性配体制造园区和放射性配体研发平台。礼来希望通过收购Point Biopharma将其肿瘤学业务拓展到下一代放射性配体疗法。</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"https://static.tigerbbs.com/c7da52addfd52fb216bcf87283f43750","relate_stocks":{"LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","PNT":"POINT BIOPHARMA GLOBAL INC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","BK4581":"高盛持仓","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","SG9999014906.USD":"大华全球优质成长基金Acc USD","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0122379950.USD":"贝莱德世界健康科学A2","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","LLY":"礼来"},"source_url":"","is_english":false,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1150270900","content_text":"10月3日，Point Biopharma盘前直线涨超82%，礼来将以12.50美元/股的现金价格收购Point Biopharma。交易总金额约为14亿美元，该交易不受任何融资条件的约束，交易预计将于2023年底完成。资料显示，Point Biopharma成立于2019年，该公司专注于用于治疗癌症的下一代放射性药物的开发和商业化。该公司还拥有大型放射性配体制造园区和放射性配体研发平台。礼来希望通过收购Point Biopharma将其肿瘤学业务拓展到下一代放射性配体疗法。","news_type":1,"symbols_score_info":{"LLY":1,"PNT":1.1}},"isVote":1,"tweetType":1,"viewCount":1013,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["JD"],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":19,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}